Cologne, 23st Jan 2020 – Last Friday, Cannamedical® Pharma GmbH, the German pioneer and one of the leading independent medical cannabis suppliers in Europe, initiated a Medical Advisory Board bringing together important stakeholders and experts in the field.

This meeting held under the title of “Medicinal cannabis – Options and new perspectives for the patient”, was an exchange between the Medical Affairs Team of Cannamedical® and leading experts in medicinal cannabis treatment. Medical/scientific as well as pharmacoeconomic aspects were discussed and initial premises for achievement of communal goals were identified.

“It is our aim to identify gaps in evidence and to close these gaps communally via close collaboration with physicians, health insurance companies, professional associations and political representatives.“ With the following words, Prof. Dr. Kirsten Müller-Vahl summarized the result-oriented approach. “Evidence requires time and in the meantime we need good interim solutions.“

Cannamedical® Pharma was able to attract a first class advisory board involving university professors and other experts from various fields of specialization such as pain therapy and neurology as well as a representative from a public health insurance company.

According to Dr. Thomas Baur, Chief Commercial Officer of Cannamedical® Pharma “The discussion about chances and limits of treatment with medicinal cannabis as well as the current experiences of patients, physicians and health insurance providers yielded valuable ideas and conclusions which clearly confirm our commitment to extend and sponsor collaboration with experts from clinical practice and science.“ Prof. Dr. Dr. Joachim Nadstawek emphasized the current situation of patients: “It is still a major challenge for patients to find an experienced cannabis prescribing doctor.“  

Cannamedical® will continue to strive for easier access to medicinal cannabis treatment for severely ill patients and to support members of the relevant specialist groups by supplying comprehensive and well researched information.

Press contact

Sandra Grußbach
E-Mail: presse@cannamedical.de
Phone: +49 221 999 852 51

About Cannamedical^® Pharma GmbH

We at Cannamedical^® Pharma GmbH are committed to helping doctors, medical specialists and pharmacists to improve their patients’ quality of life. The top-class products by Cannamedical concentrate on helping people with chronic illnesses to lead the best possible life with medicinal cannabis. To this end, we import and process only high-quality medicinal cannabis products and supply them to around 2,500 pharmacies and clinical facilities.
As well as the provision of top-class medicinal cannabis products, our focus is on training medical professionals, and providing sector-leading customer service. Our production partners worldwide must comply with the highest pharmaceutical quality standards – the so-called GMP guidelines (Good Manufacturing Practice). With its quality management, Cannamedical guarantees the highest product standards. We ourselves are GDP-certified (Good Distribution Practice), in other words, our entire supply chain is guaranteed, from the agricultural environment to the pharmacy. Cannamedical^® Pharma GmbH was founded in Cologne in 2016 and employs more than 50 staff. In addition, Cannamedical operates subsidiaries in Canada and the UK.

For more information, visit www.cannamedical.com.